Abciximab
Chemical
Monoclonal Ab 7E3 (a human-mouse monoclonal clone)
Use
- In patients undergoing PCI to prevent ischaemic complications
- Patients with unstable angina (refractory) where PCI is planned
Presentation
5mL vial with 10mg ABCIXIMAB
Dose
0.25mg/kg bolus
10mcg/min infusion
Route
IV
Onset
Immediate
DoA
Initial t½ 10 min
Second phase t ½ 30 secs
↓
Disappears from plasma because binds rapidly to GP IIb/IIIa receptors
↓
Platelet function recovers in 48hrs
MoA
- Binds GP IIb/IIIa receptor
- Inhibits platelet aggregation by preventing binding of Fibrinogen, vWF & other adhesive molecules
Reversal: platelet transfusion
PD
- Rapid & profound platelet inhibition
- Median bleeding time > 30 mins (from baseline 5min)
- Cessation of infusion restores bleeding time to <12 min in 12hrs in 75% population
PK
A
D
Rapidly binds all GP IIb/IIIa receptors
M
E
Adverse Effects
- Huge bleeding risk
- Thrombocytopaenia – can be rapid and profound, ie Plts <50 in some circumstances